AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
Blue Cross Blue Shield of Texas will stop covering certain asthma infusion treatments in clinics, obliging patients to self-inject the drugs at home. The provider will cut this coverage from its plans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback